Published in Am J Respir Crit Care Med on August 01, 1999
Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. J Cardiovasc Pharmacol (2016) 1.39
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax (2005) 1.29
Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem (2008) 1.13
Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial. PLoS One (2012) 0.99
Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther (2013) 0.94
Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol (2007) 0.91
Lung involvement in systemic sclerosis. Presse Med (2010) 0.90
Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag (2009) 0.87
Treatment of pulmonary hypertension. Med Sci Monit (2012) 0.87
Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2015) 0.85
Pulmonary hypertension survival effects and treatment options in cystic fibrosis. Curr Opin Pulm Med (2013) 0.83
Renal disease in systemic sclerosis with normal serum creatinine. Clin Rheumatol (2010) 0.82
Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol (2007) 0.81
Prostacyclin: an inflammatory paradox. Front Pharmacol (2011) 0.79
Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease. Can Respir J (2010) 0.78
Recent strategies in treatment of pulmonary arterial hypertension, a review. Glob J Health Sci (2015) 0.76
Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int (2005) 0.76
Pulmonary hypertension caused by sarcoidosis. Clin Chest Med (2008) 0.76
[Diagnosis and therapy of chronic pulmonary hypertension]. Clin Res Cardiol (2007) 0.75
Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension. Pulm Circ (2015) 0.75
Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Can Respir J (2017) 0.75
Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis. J Thorac Dis (2015) 0.75
"A small leak will sink a great ship": hypoxia-inducible factor and group III pulmonary hypertension. Receptors Clin Investig (2016) 0.75
The limits of oral therapy in pulmonary arterial hypertension management. Ther Clin Risk Manag (2015) 0.75
Severe pulmonary hypertension and right ventricular failure. Indian J Anaesth (2017) 0.75
Pulmonary hypertension associated with lung diseases and hypoxemia. Heart Fail Rev (2016) 0.75
Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med (1998) 7.34
Sildenafil treatment for portopulmonary hypertension. Eur Respir J (2006) 2.58
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med (2000) 2.55
Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood (1990) 2.54
Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J (2010) 2.51
Neoalveolarisation contributes to compensatory lung growth following pneumonectomy in mice. Eur Respir J (2007) 2.11
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med (2000) 1.95
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med (1996) 1.87
Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am J Physiol Lung Cell Mol Physiol (2001) 1.85
Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med (1996) 1.79
Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet (1993) 1.74
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol (2000) 1.73
The dorsolateral, suboccipital, transcondylar approach to the lower clivus and anterior portion of the craniocervical junction. Neurosurgery (1991) 1.67
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J (2008) 1.62
Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol (1988) 1.61
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Staphylococcal alpha-toxin-induced PGI2 production in endothelial cells: role of calcium. Am J Physiol (1985) 1.57
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med (2000) 1.57
Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2000) 1.54
[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie (2002) 1.48
Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J (2010) 1.47
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J (2009) 1.44
Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985) (1985) 1.44
Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium. J Clin Invest (1984) 1.43
Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med (2001) 1.43
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med (1996) 1.42
Characterisation of post-pneumonectomy lung growth in adult mice. Eur Respir J (2004) 1.39
Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release (2005) 1.38
The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies. Am J Respir Crit Care Med (2000) 1.36
Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J (1996) 1.35
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J (2002) 1.35
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost (2000) 1.33
Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. J Immunol (2000) 1.32
Mechanism of leukotriene generation in polymorphonuclear leukocytes by staphylococcal alpha-toxin. Infect Immun (1987) 1.30
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J (2010) 1.28
Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J (2002) 1.27
Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax (2000) 1.27
Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis (1989) 1.27
Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. Eur Respir J (2008) 1.24
Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res (2001) 1.23
Human endothelial cell activation and mediator release in response to the bacterial exotoxins Escherichia coli hemolysin and staphylococcal alpha-toxin. J Immunol (1997) 1.23
Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol (2000) 1.22
Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice. Am J Respir Crit Care Med (2001) 1.21
Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol (2006) 1.19
The listerial exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C synergize to elicit endothelial cell phosphoinositide metabolism. J Immunol (1996) 1.17
Human endothelial cell activation and mediator release in response to Listeria monocytogenes virulence factors. Infect Immun (2001) 1.16
Microsurgical unilateral approaches for spinal tumour surgery: eight years' experience in 256 primary operated patients. Acta Neurochir (Wien) (1989) 1.16
Effects of Escherichia coli hemolysin on endothelial cell function. Infect Immun (1990) 1.16
Escherichia coli hemolysin is a potent inductor of phosphoinositide hydrolysis and related metabolic responses in human neutrophils. J Clin Invest (1991) 1.13
Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol (1986) 1.13
Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med (2001) 1.13
Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation. J Exp Med (1996) 1.12
Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation (2000) 1.12
Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia. Acta Neurochir (Wien) (1995) 1.12